Daily low dose thalidomide plus monthly high-dose dexamethasoneas consolidation/maintenance treatment in elderly multiple myeloma patients

被引：0
|
作者：
Gentile, M.
Mazzone, C.
Iorio, C.
Lucia, E.
Vigna, E.
Mazzei, F.
Carnevale, P.
Bisconte, M. G.
Gentile, C.
Morabito, F.
机构：
[1] Haematol Unit, Cosenza, Italy
[2] Pharm Unit, Cosenza, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0255
引用
下载
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [21] A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
    Lokhorst, Henk M.
    van der Holt, Bronno
    Zweegman, Sonja
    Vellenga, Edo
    Croockewit, Sandra
    van Oers, Marinus H.
    Borne, Peter von dem
    Wijermans, Pierre
    Schaafsma, Ron
    de Weerdt, Okke
    Wittebol, Shulamiet
    Delforge, Michel
    Berenschot, Henriette
    Bos, Gerard M.
    Jie, Kon-Siong G.
    Sinnige, Harm
    van Marwijk-Kooy, Marinus
    Joosten, Peter
    Minnema, Monique C.
    van Ammerlaan, Rianne
    Sonneveld, Pieter
    BLOOD, 2010, 115 (06) : 1113 - 1120
  • [22] Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma
    Fenk, R
    Hoyer, B
    Steidl, U
    Kondakci, M
    Graef, T
    Heuk, R
    Ruf, L
    Strupp, C
    Neumann, F
    Rohr, UP
    Hildebrandt, B
    Haas, R
    Kobbe, G
    LEUKEMIA, 2005, 19 (01) : 156 - 159
  • [23] LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW
    Kupas, K.
    Kaspar, I.
    Baecke, V.
    Weisel, K.
    HAEMATOLOGICA, 2017, 102 : 514 - 515
  • [24] Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma
    R Fenk
    B Hoyer
    U Steidl
    M Kondakci
    T Graef
    R Heuk
    L Ruf
    C Strupp
    F Neumann
    U-P Rohr
    B Hildebrandt
    R Haas
    G Kobbe
    Leukemia, 2005, 19 : 156 - 159
  • [25] HIGH-DOSE MELPHALAN IS A SAFE CONDITIONING REGIMEN IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA
    Cangini, D.
    Cerchione, C.
    Giannini, M. B.
    Di Battista, V.
    Frabetti, F.
    Petracci, E.
    Ronconi, S.
    Martinelli, G.
    HAEMATOLOGICA, 2019, 104 : 163 - 163
  • [26] Successful Treatment of Extramedullary Tumors with Low-dose Thalidomide in Patients with Multiple Myeloma
    Yasuda, Hajime
    Ando, Jun
    Sato, Eriko
    Inagaki, Naoko
    Aritaka, Nanae
    Komatsu, Norio
    Hirano, Takao
    INTERNAL MEDICINE, 2010, 49 (23) : 2617 - 2620
  • [27] Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma
    Chang, Julie E.
    Juckett, Mark B.
    Callander, Natalie S.
    Kahl, Brad S.
    Gangnon, Ronald E.
    Mitchell, Teri L.
    Longo, Walter L.
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (03): : 153 - 158
  • [28] Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy
    Corso, A.
    Mangiacavalli, S.
    Barbarano, L.
    Montalbetti, L.
    Mazzone, A.
    Fava, S.
    Varettoni, M.
    Zappasodi, P.
    Morra, E.
    Lazzarino, M.
    LEUKEMIA RESEARCH, 2008, 32 (07) : 1085 - 1090
  • [29] THE MAINTENANCE THERAPY WITH THALIDOMIDE IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA
    Bila, J.
    Lekovic, D.
    Smiljanic, M.
    Sretenovic, A.
    Andjelic, B.
    Vidovic, A.
    Todorovic, M.
    Elezovic, I.
    Tomin, D.
    Gotic, M.
    Mihaljevic, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 583 - 583
  • [30] Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: A Chinese experience
    Guo, Hongfeng
    Zhou, Xin
    Jiang, Yuanqiang
    Yang, Guohua
    Sun, Chao
    Zhuang, Yun
    Sun, Hongli
    Lu, Mize
    Qian, Xifeng
    Chen, Feng
    Mao, Jingjue
    Chen, Heng
    Xia, Jun
    Shen, Yunfeng
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (07) : 499 - 501
12345